Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects

• Published in: Journal of clinical pharmacology Vol. 45; no. 5; p. 519
• Main Authors: Yao, Caiping, Raoufinia, Arash, Gold, Michael, Nye, Jeffrey S, Ramael, Steven, Padmanabhan, Mukund, Walschap, Yolande, Verhaeghe, Tom, Zhao, Qinying
• Format: Journal Article
• Language: English
• Published: England 01.05.2005
• Subjects: Adult; Area Under Curve; Cholinesterase Inhibitors - administration & dosage; Cholinesterase Inhibitors - adverse effects; Cholinesterase Inhibitors - pharmacokinetics; Delayed-Action Preparations; Drug Interactions; Female; Galantamine - administration & dosage; Galantamine - adverse effects; Galantamine - pharmacokinetics; Half-Life; Humans; Male; Memantine - adverse effects; Memantine - pharmacokinetics; Memantine - pharmacology; Middle Aged; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors
• ISSN: 0091-2700
• DOI: 10.1177/0091270005274551

To evaluate the effect of multiple doses of memantine on the pharmacokinetics of galantamine and to assess the safety and tolerability of galantamine with adjunctive memantine treatment, an open-label, single-center, drug interaction study was conducted in 16 healthy adults. Subjects received an 8-mg dose of galantamine extended release once daily during week 1 and a 16-mg dose of galantamine extended release once daily during week 2. During weeks 3 and 4, they received a 16-mg dose of galantamine extended release once daily and a 10-mg dose of memantine twice daily, except on days 1 and 2 of week 3, when memantine was given as 10 mg once daily. The pharmacokinetic profile and parameters of galantamine at steady state were similar after administration of a 16-mg dose of galantamine once daily alone and after administration with a 10-mg dose of memantine twice daily. Galantamine 16 mg once daily with adjunctive memantine 10 mg twice daily was well tolerated and safe in healthy subjects.